Compare Boston Scientific Corporation (BSX) vs HubSpot Inc (HUBS) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Boston Scientific Corporation vs HubSpot Inc — how do they compare? Boston Scientific Corporation trades at $51.68 (market cap $74.19B), while HubSpot Inc trades at $208.36 (market cap $11.00B). The key difference: Boston Scientific Corporation is far larger — about 6.7× HubSpot Inc's market cap. Which is the better fit depends on your goals.
| BSX | HUBS | |
|---|---|---|
Market Cap | $74.19B | $11.00B |
Sector | Health | Technology |
52-Week High | $108.14 | $522.97 |
52-Week Low | $42.63 | $170.39 |
Enterprise Value | $86.27B | $9.89B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Boston Scientific (BSX) trades at $51.27, up 1.6% with strong technical momentum and bullish moving averages. The company delivered three consecutive quarterly EPS beats in 2026, with Q2 EPS of $0.86 exceeding expectations. Revenue grew to $20.07B in 2025 with a 14.4% net margin, while analyst consensus shows 86% buy ratings with a $67.21 price target. Recent insider buying by the CEO and director signals confidence despite near-term guidance challenges.
BSX presents attractive valuation with 44% upside to consensus target, supported by strong fundamentals and institutional support. Key risks include competitive pressures in WATCHMAN and electrophysiology segments, along with elevated RSI levels suggesting potential near-term consolidation. The long-term growth trajectory remains intact with 2026 revenue projected at $21B and 17.5% margins.
HubSpot (HUBS) trades at $210.92, down 2.31% on the day, amid a bearish technical signal and recent stock volatility following Q2 2026 results. The company reported strong earnings beats but lowered its customer-growth forecast, contributing to a sharp price decline from previous highs. Revenue growth remains robust at 20% year-over-year, yet high valuation multiples and margin pressures present challenges. Analyst sentiment is predominantly bullish with a $233.93 consensus target, but near-term execution risks and increased AI spending weigh on investor confidence.
The outlook for HUBS hinges on successful execution of its AI-driven strategy amid slower customer acquisition. Investment opportunity lies in its solid revenue growth and market position if it can navigate budget scrutiny and competitive pressures. Key risks include heightened execution risks, potential securities litigation, and the financial impact of strategic shifts, which could limit near-term upside despite long-term transformation potential.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Boston Scientific Corporation
Boston Scientific produces less invasive medical devices that are inserted into the human body through small openings or cuts. It manufactures products for use in angioplasty, blood clot filtration, cardiac rhythm management, catheter-directed ultrasound imaging, structural heart disease, upper gastrointestinal tract diagnostics, interventional oncology, and treatment of incontinence. The firm markets its devices to healthcare professionals and institutions globally. Foreign sales account for nearly half of the firm's total sales.
Read more on BSX →About HubSpot Inc
HubSpot provides a cloud-based marketing, sales, and customer service software platform referred to as the growth platform. The applications are available ala carte or packaged together. HubSpot's mission is to help companies grow better and has expanded from its initial focus on inbound marketing to embrace marketing, sales, and service more broadly. The company was founded in 2006, completed its initial public offering in 2014, and is headquartered in Cambridge, Massachusetts.
Read more on HUBS →
